[go: up one dir, main page]

TN2013000115A1 - Pharmaceutical combinations - Google Patents

Pharmaceutical combinations

Info

Publication number
TN2013000115A1
TN2013000115A1 TNP2013000115A TN2013000115A TN2013000115A1 TN 2013000115 A1 TN2013000115 A1 TN 2013000115A1 TN P2013000115 A TNP2013000115 A TN P2013000115A TN 2013000115 A TN2013000115 A TN 2013000115A TN 2013000115 A1 TN2013000115 A1 TN 2013000115A1
Authority
TN
Tunisia
Prior art keywords
combination
mtor
treatment
simultaneous
separate
Prior art date
Application number
TNP2013000115A
Other languages
English (en)
Inventor
Yan Chen
Xizhong Huang
Leon Murphy
Beat Nyfeler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/054536 external-priority patent/WO2012047775A1/fr
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2013000115A1 publication Critical patent/TN2013000115A1/fr

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2013000115A 2011-10-03 2013-03-18 Pharmaceutical combinations TN2013000115A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/054536 WO2012047775A1 (fr) 2010-10-04 2011-10-03 Combinaisons pharmaceutiques

Publications (1)

Publication Number Publication Date
TN2013000115A1 true TN2013000115A1 (en) 2014-06-25

Family

ID=54360795

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000115A TN2013000115A1 (en) 2011-10-03 2013-03-18 Pharmaceutical combinations

Country Status (1)

Country Link
TN (1) TN2013000115A1 (fr)

Similar Documents

Publication Publication Date Title
PH12013500581A1 (en) Pharmaceutical combinations
MX2009008486A (es) Imidazoquinolinas como inhibidores dobles de cinasa de lipido y mtor.
PH12012502161A1 (en) Pharmaceutical formulations comprising pioglitazone and linagliptin
MX2013012588A (es) Inhibidores de cinasa.
IL231226A (en) Compounds and preparations as kinase c-kit inhibitors, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of diseases
AU2016219653A1 (en) Crystallization Method and Bioavailability
WO2009007749A3 (fr) Composés 947
GB201118656D0 (en) New compounds
WO2013052699A3 (fr) Nouveaux inhibiteurs de quinoxaline de la voie pi3k
MX349004B (es) Nuevos compuestos.
BR112014018910A8 (pt) Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores
TN2013000392A1 (en) Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
UA106634C2 (uk) Тверда фармацевтична дозована форма
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
WO2011086531A3 (fr) Nouveaux agents antipaludiques
WO2011157416A3 (fr) Administration transdermique de mémantine
PH12014500809A1 (en) Polymorphs of arry-380, a slective herb2 inhibitor and pharmaceutical compositions containing them
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
WO2013071056A3 (fr) Polythérapie médicamenteuse pour le traitement de tumeurs solides
CR20110338A (es) Formulaciones de imiquimod de baja concentración de dosis y regimenes de dosis de corta duración para tratar queratosis actínica
AR085183A1 (es) Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
MX369518B (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
IN2014DN01619A (fr)
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM